| Literature DB >> 31020034 |
James E Feng1, Jonathan A Gabor1, Afshin A Anoushiravani2, William J Long1, Jonathan M Vigdorchik1, Patrick A Meere1, Richard Iorio3, Ran Schwarzkopf1, William Macaulay1.
Abstract
BACKGROUND: There is a paucity of literature assessing whether payer type has an impact on postoperative patient-reported outcomes (PROs) after total knee arthroplasty (TKA). The aim of this study was to comparatively evaluate TKA PROs among patients with commercial and Medicare insurance.Entities:
Keywords: Insurance; Medicare; Patient-reported outcomes; Total knee arthroplasty
Year: 2019 PMID: 31020034 PMCID: PMC6470348 DOI: 10.1016/j.artd.2018.11.004
Source DB: PubMed Journal: Arthroplast Today ISSN: 2352-3441
Demographics.
| Demographic and surgical variables | Commercial (n = 91) | Medicare (n = 102) | Medicaid (n = 5) | Worker’s compensation (n = 3) | |
|---|---|---|---|---|---|
| Age | 60.12 ± 7.29 | 70.50 ± 5.86 | <.00001 | 57.00 ± 4.18 | 59.00 ± 8.19 |
| Gender | <.05 | ||||
| Female | 49 (52.68%) | 68 (66.67%) | 3 (60.00%) | 0 | |
| Male | 44 (47.31%) | 34 (33.33%) | 2 (40.00%) | 3 (100.00%) | |
| BMI | 32.97 ± 6.69 | 30.38 ± 6.01 | <.01 | 33.74 ± 5.59 | 32.77 ± 4.94 |
| ASA | <.05 | ||||
| 1 | 5 (5.38%) | 0 | 0 | 0 | |
| 2 | 55 (59.14%) | 50 (49.02%) | 2 (40.00%) | 2 (66.67%) | |
| 3 | 31 (33.33%) | 50 (49.02%) | 3 (60.00%) | 1 (33.33%) | |
| 4 | 2 (2.15%) | 2 (1.96%) | 0 | 0 | |
| Median | 2 | 3 | |||
| Race | <.05 | ||||
| African-American (black) | 19 (20.43%) | 8 (7.84%) | 1 (20.00%) | 0 | |
| Asian | 0 | 3 (2.94%) | 0 | 0 | |
| White | 64 (68.82%) | 84 (82.35%) | 2 (40.00%) | 3 (100.00%) | |
| Other | 10 (10.75%) | 7 (6.86%) | 2 (40.00%) | 0 | |
| Marital status | .10 | ||||
| Married/partner | 60 (64.52%) | 51 (50.00%) | 3 (60.00%) | 2 (66.67%) | |
| Divorced/separated | 5 (5.38%) | 12 (11.76%) | 1 (20.00%) | 1 (33.33%) | |
| Single/widowed | 28 (30.11%) | 39 (38.24%) | 1 (20.00%) | 0 | |
| Surgical time | 111.67 ± 34.83 | 106.76 ± 37.53 | .27 | 119.40 ± 45.85 | 100.33 ± 47.72 |
| Length of stay | 2.10 ± 1.38 | 2.23 ± 1.26 | .50 | 2.20 ± 1.64 | 2.67 ± 2.08 |
| Discharge disposition | .15 | ||||
| Home with self-care | 9 (9.68%) | 8 (7.84%) | 0 | 0 | |
| Home health services | 80 (86.02%) | 86 (84.31%) | 5 (100.00%) | 3 (100.00%) | |
| Skilled nursing | 1 (1.08%) | 7 (6.83%) | 0 | 0 | |
| Acute rehab | 3 (3.23%) | 1 (0.98%) | 0 | 0 |
Denotes a statistically significant difference between commercial and medicare cohorts (P < .05).
TKA PRO scores relative to commercial insurance.
| Patient reported outcomes | Commercial | Medicare | Medicaid | Worker’s compensation | |
|---|---|---|---|---|---|
| Preoperative PROs | |||||
| KOOS JR. | 47.78 ± 11.82 | 51.91 ± 13.88 | <.05 | 50.76 ± 22.57 | 46.34 ± 10.81 |
| VR-12 PCS | 32.92 ± 8.55 | 32.19 ± 8.62 | .53 | 33.28 ± 11.32 | 23.15 ± 2.78 |
| VR-12 MCS | 49.47 ± 12.35 | 49.65 ± 11.68 | .96 | 41.77 ± 11.87 | 45.55 ± 10.59 |
| 12 weeks postop PROs | |||||
| KOOS JR. | 67.47 ± 13.62 | 70.26 ± 12.61 | .15 | 62.42 ± 6.10 | 66.49 ± 9.60 |
| VR-12 PCS | 40.11 ± 8.48 | 40.03 ± 7.89 | .76 | 43.72 ± 3.00 | 33.22 ± 9.01 |
| VR-12 MCS | 55.00 ± 8.97 | 53.40 ± 9.91 | .26 | 44.17 ± 4.49 | 50.72 ± 19.52 |
| ΔPROs | |||||
| KOOS JR. | 19.69 ± 15.44 | 18.35 ± 15.92 | .58 | 12.34 ± 18.77 | 20.15 ± 19.17 |
| VR-12 PCS | 6.68 ± 10.21 | 7.85 ± 9.04 | .41 | 10.44 ± 8.78 | 10.07 ± 6.95 |
| VR-12 MCS | 5.24 ± 11.66 | 3.74 ± 10.59 | .36 | 2.40 ± 11.60 | 9.17 ± 9.45 |
Denotes a statistically significant difference between commercial and medicare cohorts (P < .05).
Figure 1KOOS JR. scores at preoperative, 6-week postoperative, and 12-week postoperative time points.
Figure 2VR-12 PCS at preoperative, 6-week postoperative, and 12-week postoperative time points.
Figure 3VR-12 MCS at preoperative, 6-week postoperative, and 12-week postoperative time points.
Adjusted TKA PRO scores relative to commercial insurance.
| Patient reported outcomes | Commercial | Medicare | Model | |
|---|---|---|---|---|
| Preoperative PROs | ||||
| KOOS JR. | Reference | −0.63 ± 2.40 | .79 | <.01 |
| VR-12 PCS | Reference | 0.29 ± 2.49 | .91 | <.05 |
| VR-12 MCS | Reference | 0.91 ± 3.06 | .77 | .17 |
| 12 weeks postop PROs | ||||
| KOOS JR. | Reference | −1.99 ± 1.65 | .23 | <.01 |
| VR-12 PCS | Reference | 0.22 ± 1.60 | .89 | .08 |
| VR-12 MCS | Reference | 2.21 ± 1.90 | .25 | .17 |
| ΔPROs | ||||
| KOOS JR. | Reference | 0.56 ± 2.40 | .82 | .48 |
| VR-12 PCS | Reference | −1.06 ± 1.96 | .59 | .89 |
| VR-12 MCS | Reference | −1.62 ± 2.25 | .47 | .67 |